LON:SVNS Solvonis Therapeutics 9/30/2025 Earnings Report GBX 0.24 +0.02 (+8.89%) As of 05/15/2026 12:06 PM Eastern ProfileEarnings History Solvonis Therapeutics EPS ResultsActual EPS-GBX 0.06Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ASolvonis Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASolvonis Therapeutics Announcement DetailsQuarterDate9/30/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Solvonis Therapeutics Earnings HeadlinesSolvonis pivots strategy to carry lead AUD drug through Phase 3 amid sector tailwindsApril 29, 2026 | tipranks.comSolvonis wins second U.S. patent to deepen PTSD therapy IPApril 8, 2026 | tipranks.comElon Musk’s $1 Quadrillion AI IPO$1 quadrillion would be enough to send a $2.8 million check to every man, woman, and child in America. That is the scale of what analysts are calling the biggest AI IPO in history.And right now, you can claim a stake before the company goes public, starting with just $500.Elon Musk is predicting this investment could climb 1,000x from here. Early access is available today.May 17 at 1:00 AM | Brownstone Research (Ad)Solvonis Extends Novel SDRI SVN‑015 Into Depression After Positive Preclinical ResultsJanuary 28, 2026 | tipranks.comSolvonis’ SVN-015 Accepted into NIDA Program for Addiction TreatmentDecember 3, 2025 | tipranks.comSolvonis Therapeutics Updates Share Capital DetailsOctober 31, 2025 | tipranks.comSee More Solvonis Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Solvonis Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Solvonis Therapeutics and other key companies, straight to your email. Email Address About Solvonis TherapeuticsSolvonis Therapeutics (LON:SVNS) plc is a clinical-stage biopharmaceutical company headquartered in the United Kingdom. The company is developing a proprietary synthetic exosome platform designed to enhance the targeted delivery of therapeutic compounds. By engineering nanoscale vesicles that mimic natural exosomes, Solvonis aims to improve tissue selectivity, increase payload stability and enable efficient transport of small molecules, peptides and nucleic acids across biological barriers. The company’s lead programs focus on oncology and central nervous system disorders, where delivery challenges have historically limited the efficacy of novel therapeutics. Solvonis’ modular vesicle system can be customized to carry a range of payloads and surface ligands, allowing for precision targeting of solid tumours or neural tissues. Preclinical studies are ongoing to assess safety, biodistribution and therapeutic activity in relevant disease models. Solvonis collaborates with academic institutions and contract research organizations to advance its pipeline through preclinical development. With operations centred in the UK and strategic partnerships in place, the company is positioning its synthetic exosome technology as a next-generation delivery solution for the global biopharmaceutical industry.View Solvonis Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Peloton Stock Gives Back Gains After Upbeat Earnings ReportDatavalut Gains Traction: 5 Reasons to Sell NowTMC Stock: Why This Pre-Revenue Miner Is Worth WatchingViking Sails to All-Time Highs—Fundamentals Signal More to ComeYETI Rallies After Earnings Beat and Raised OutlookAeluma's Post-Earnings Dip Creates a Buying OpportunityCisco’s Vertical Rally May Still Be in the Early Innings Upcoming Earnings Palo Alto Networks (5/19/2026)Home Depot (5/19/2026)Keysight Technologies (5/19/2026)Analog Devices (5/20/2026)Intuit (5/20/2026)NVIDIA (5/20/2026)Lowe's Companies (5/20/2026)Medtronic (5/20/2026)Target (5/20/2026)TJX Companies (5/20/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
